The appointment of statins in patients with hypothyroidism: possible risks
Abstract
Thyroid dysfunction and dyslipidemia are closely connected by pathogenetic reason. During the last few years they have been discussing L-thyroxin influence on lipid profile. According to data obtained in various studies, lipid profile values normalization appears not in every case of euthyroidism. In the literature there is little information about statins administration risk and advantage during hypothyroidism. According to the literature, decompensated hypothyroidism can lead to myalgia and / or myopathy development accompanied by creatine phosphokinase concentration increase in patients on statins. There are several publications of clinical cases of rhabdomyolysis development against the statins treatment background in persons with undiagnosed decompensated manifest hypothyroidism. Thus, taking into account the risk of the rhabdomyolysis development, TSH level should be estimated before statins treatment almost in all cases.
About the Authors
O D. Rymar
RAMS
Russian Federation
Russian Federation
SB RAMS
Establishment of the Russian Academy of Medical Sciences Research Institute of Therapy
630089
st. Boris Bogatkov, 175/1
Novosibirsk
S. V. Mustafina
RAMS
Russian Federation
Russian Federation
SB RAMS
Establishment of the Russian Academy of Medical Sciences Research Institute of Therapy
630089
st. Boris Bogatkov, 175/1
Novosibirsk
Ya. A. Malyshenko
RAMS
Russian Federation
Russian Federation
SB RAMS
Establishment of the Russian Academy of Medical Sciences Research Institute of Therapy
630089
st. Boris Bogatkov, 175/1
Novosibirsk
References
1. Gupta A., Sinha R. S. Echocardiographic changes and alterations in lipid profile in cases of subclinical and overt hypothyroidism // J. Assoc. Physicians India. 1996. Vol. 44. P. 546, 551–553.
2. Hak A. E., Pols H., Visser T. J. et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women the Rotterdam study // Ann. Intern. Med. 2000. Vol. 132, N 4. P. 270–278.
3. Michalopoulou G., Alevizaki M., Piperingos G. et al. High serum cholesterol levels in persons with ‘high-normal’ TSH levels: should one extend the definition of subclinical hypothyroidism?// Eur. J. Endocrinol. 1998. Vol. 138, N 2. Р. 141–145.
4. Diekman T., Lansberg P. J., Kastelein J. J. et al. Prevalence and correction of hypothyroidism in a large cohort of patients refered for dyslipidemia // Arch. Intern. Med. 1995. Vol. 155, N 14. Р. 1490–1495.
5. Duntas L. H. Thyroid disease and lipids // Thyroid. 2002. Vol. 12. P. 287–293.
6. Franklyn J. A., Daykin J., Betteridge J. et al. Sheppard Thyroxine replacement therapy and circulating lipid concentrations // Clin. Endocrinol. 1993. Vol. 38, N 5. Р. 453–459.
7. Caron P., Calazel С., Parra H. J. et al. Decreased HDL cholesterol in subclinikal hypothyroidism: the effect of L-thyroxine therapy // J. Clin. Endocrinol. 1990. Vol. 33. P. 519–523.
8. Althaus B. U., Staub J. J., De Luche A. R. et al. LDL / HDL-changes in subclinical hypothyroidism:possible risk factors for coronary artery disease // Clin. Endocrinol. 1988. Vol. 28. P. 157–163.
9. Park K. W., Dai H. B., Ojamaa K. et al. The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries // Anesth. Analg. 2002. Vol. 85. P. 734–738.
10. Фадеев В. В. Заболевания щитовидной железы в регионе легкого йододефицита: эпидемиология, диагностика, лечение / В. В. Фадеев. – М.: Видар, 2005. – 238 с.
11. Tanis B. C., Westendop R. G. J., Smelt A. H. M. Effect of thyroid substitution on hypercholesterolemia in patients with subclinical hypothyroidism: A reanalysis of intervention studies // Clin. Endocrinol. 1996. Vol. 44, N 6. P. 643–649.
12. Wiseman S. A., Powell J. T., Humphries S. E., Press M. The magnitude of the hypercholesterolemia of hypothyroidism is associated with variation in the low density lipoprotein receptor gene // J. Clin. Endocrinol. Metab. 1993. Vol. 72, N 1. P. 108–112.
13. Caracio N., Ferrannini E., Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controiier stydy// J. Clin. Endocrinol. Metab. 2002. Vol. 87. P. 1533–1538.
14. Mya M. M., Aronow W. S., Gerontol A. Subclinical hypothyroidism is associated with coronary artery disease in older persons // Biol. Sci. Med. Sci. 2002. Vol. 57, N 10. P. 658–659.
15. Kim S. K., Kim S. H., Park K. S. et al. Regression of the increased common carotid artery-intima media thickness in subclinical hypothyroidism after thyroid hormone replacement // Endocr. J. 2009. Vol. 56, N 6. Р. 753–758.
16. Мустафина С. В. Функциональное состояние щитовидной железы и липидный профиль / С. В. Мустафина [и др.] // Атеросклероз. – 2010. – Т. 6, № 2. – С. 15–20.
17. Tomlinson B., Lan W. Hypothyroidism and simvastatin // HKMJ. 2001. Vol. 7, N 2. P. 219–220.
18. Товажнянская Е. Л. Аторвастатин в лечении больных первичным гипотиреозом с неврологическими осложнениями и гиперлипидемией / Е. Л. Товажнянская // Междунар. мед. журн. – 2008. – № 2. – C. 22–26.
19. Hung Y. T., Yeung V. T. F. Hypothyroidism presenting as hypercholesterolaemia and simvastatin-induced myositis // HKMJ. 2000. N 6. Р. 423–424.
20. Hamilton C. I. Statin-associated myopathy // Med. J. Aust. 2001. Vol. 175, N 9. Р. 486–489.
21. Lang J., Wang P., Glueck C. Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism // Clin. Chim. Acta. 1996. Vol. 254. P. 65–92.
22. Lin R. T., Liu C. K., Tai C. T. et al. Hypothyroid myopathy – pathological and ultrastructural study // Kaohsiung J. Med. Sci. 2000. N 16. Р. 68–75.
23. Prudhomme F., Jacotot B. Muscular toxicity of antilipemic agents revealed during the course of hypothyroidism // Presse Med. 2003. N 32. Р. 1031–1032.
24. Łukjanowicz M., Trzcińska-Butkiewicz B., Brzosko M. Miopatia spowodowana stosowaniem fenofibratu u osoby z nierozpoznaną niedoczynnością tarczycy – opis przypadku i przegląd piśmiennictwa // Pol. Arch. Med. Wewn. 2006. Vol. 115. P. 45–49.
25. Thompson P. D., Clarkson P., Karas R. H. Statin-associated myopathy // JAMA. 2003. Vol. 289. Р. 1681–1690.
26. Law M., Rudnicka A. R. Statin safety: a systematic review // Am. J. Cardiol. 2006. Vol. 97, N 8A. Р. 52–60.
27. Lindner A., Zierz S. Rhabdomyolysis and myoglobinuria// Nervenarzt. 2003. Vol. 74, N 6. Р. 505–515.
28. Pasternak R. C., Smith S. C., Bairey-Merz C. N. et al. ACC / AHA / NHLBI clinical advisory on the use and safety of statins // J. Am. Coll. Cardiol. 2002. N 40. Р. 567–572.
29. Omar M. A., Willson J. P., Cox T. S. Rhabdomyolysis and HMG-COA reductase inhibitors // Ann Pharmacother. 2001. Vol. 35. P. 1096–1107.
30. Barahona M. J., Mauri A., Sucuzza N. et al. Hypothroidism as a cause of Rhabdomyolysis // Endocr. J. 2002. N 49. Р. 621–623.
31. Mc Kenney J. M. An Assessment of Statin Safety // Am. J. Manag. Care. 2006. N 12. Р. 310–317.
32. Thompson P. D., Clarkson P. M., Rosenson R. S. An Assessment of Statin Safety by Muscle Experts // Am. J. Cardiol. 2006. Vol. 97, N 8. P. 69–76.
33. Ronaldson K. J., O’Shea J. M., Boyd I. W. Risk factors for rhabdomyolysis with simvastatin and atorvastatin // Drug Saf. 2006. Vol. 29, N 11. Р. 1061–1067.
34. «Interaction between amiodarone (marketed as Zocor and generics) or Simvastatin-combination products (marketed as Vytorin and Simcor): Amiodarone potentiates the risk for simvastatin-associated rhabdomyolysis» // Drug Safety Newsletter, Summer 2008. Vol. 1, N 4.
35. Tokinaga K., Oeda T., Suziki Y., Matsushima Y. HMG CoA Reductase Inhibitors might ause high elevations of creatine phosphokinase in patients with unnoticed hypothyroidism // Endocr. J. 2006. Vol. 53. P. 401–405.
36. Yeter E., Keles T., Durmaz T., Bozkurt E. Rhabdomyolysis due to the additive effect of statin therapy and hypothyroidism: a case report // J. Med. Case Reports. 2007. 1: 130 doi:10.1186/1752-1947-1-130
37. Finsterer J. Fibrat / Statin – Myopathie// Nervenarzt. 2003. Vol. 74. P. 115–122.
38. Simona L., Bar D. T., Holmes J. F. Asymptomatic hypothyroidism and statin-induced myopathy// Canadian Family Physician. 2007. Vol. 53. Р. 428–431.
39. Kędzia A., Krysiak R., Madej A., Okopień B. Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? // Polskie archiwum medycyny wewnetrznej. 2007. Vol. 117, N 10. Р. 473–476.
Review
For citations:
Rymar O.D., Mustafina S.V., Malyshenko Ya.A. The appointment of statins in patients with hypothyroidism: possible risks. Ateroscleroz. 2012;8(2):32-38. (In Russ.)
Views:
11570
Email this article 